500 patients67,039 observations150 daysLIVE

Patient P-03451

Synthetic patientONX-7 · Day 122 · 45–54 · F · baseline S08Steering view · 3DOpen companion preview
Therapy response
Favorable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S08
  2. Day 100 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 100.

Primary contributors, last 14 days
  • Treatment adherence-15
  • Toxicity+8
  • Nutritional resilience+4
  • GI instability+2
  • Inflammatory activity+2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    62%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 83% showed improvement
    • median effect visible after 8 days

    Daily trackers

    Molecule settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Energy level
    Daily log
    3.8/10
    worsening · -1.3 vs previous 14 d
    Stress level
    Daily log
    5.7/10
    worsening · +0.7 vs previous 14 d
    Pessimism score
    Daily log
    5.3/10
    worsening · +0.2 vs previous 14 d
    Sleep quality
    Wearable
    27.4/100
    worsening · -11.2 vs previous 14 d
    Libido
    Daily log
    2.8/10
    worsening · -0.8 vs previous 14 d
    HRV
    Wearable
    50.5 ms
    worsening · -6.7 vs previous 14 d
    Toxicity
    Blood
    43.8/100
    worsening · +12.1 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 41 from the failing basin, 56 from restoration.

    Would help
    • GI-04 GI Support Protocol
      74% improved among 34 similar · onset 8 d · confidence 60%
    • ME-01 Monitoring Escalation
      100% improved among 11 similar · onset 3 d · confidence 62%
    • DT-01 Dosing / Timing Recommendation
      82% improved among 11 similar · onset 5 d · confidence 62%
    • More protein
      GI -5.4 next day on high-intake days · n 21
    Would not help
    • AD-05 Adherence Support
      only 22% improved among 9 similar
    • Keep fat low
      GI +4.4 next day on high-intake days · n 21
    • Keep histamine low
      GI +4 next day on high-intake days · n 16
    • Keep lactose low
      GI +3.1 next day on high-intake days · n 16
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -5.4supporter · 95%
    • Dietary fat load
      +4.4detractor · 95%
    • Histamine load
      +4detractor · 95%
    • Lactose
      +3.1detractor · 86%
    • Caffeine
      +1.1no signal · 22%
    • Alcohol
      +0.3no signal · 15%

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production 80
      • MicrobiomeButyrate capacity 27/100
      • MicrobiomeF. prausnitzii depleted
      • Daily logFibre intake low in recent food logs
    • Mucosal barrier integrity 60
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • Daily logGI symptom score 59 and rising
      • WearableSleep 6.1 h, below personal baseline
    • Inflammatory signalling 50
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • BloodInflammatory load index 57
    • Autonomic recovery 45
      • WearableResting HR 73 bpm
      • WearableShort sleep window
    • Drug metabolism and exposure 20
      • BloodToxicity index 44
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Intermediate metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 3.2 · butyrate capacity 27/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    52 ms
    Sleep
    6.2 h
    Steps
    6,066
    Resting HR
    73 bpm
    Daily log: GI score 59, nutritional resilience 43, adherence 70.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0304321%S1687
    P-0305621%S0584
    P-0314223%S1584
    P-0308722%S0483
    P-0304221%S1583
    P-0332422%S1482
    P-0305421%S0382
    P-0344622%S0381
    P-0319022%S0381
    P-0330222%S2081
    P-0345822%S1581
    P-0307221%S0381